Depression: Hope comes from a substance contained in hallucinogenic mushrooms
A new clinical study, known as "the largest of its kind," has found that a drug based on psilocybin , the active hallucinogen found in psychedelic mushrooms, effectively improves depression in people when given in a single dose. Psilocybin is a psychedelic tryptamine found in some hallucinogenic mushrooms of the genus Psilocybe, Panaeolus, Inocybe, and Stropharia . When ingested it is rapidly dephosphorylated to psilocin which exerts effects on the central nervous system inducing psychedelic experiences and mildly euphoric effects.
The study was conducted by COMPASS Pathways at 22 international sites, including King's College London's Institute of Psychiatry, Psychology & Neuroscience (IoPPN) and the South London and Maudsley NHS Foundation Trust.
According to the research, randomized, double-blinded, included 233 patients who took different doses: a dose of 0.00088 ounces (25 milligrams), 0.00035 ounces (10 mg) and 3.5274e-5 ounces (1 mg). ) of synthetic psilocybin, COMP360, administered together with psychological support. The researchers found that participants who took the higher dosage reported a greater reduction in depression levels three weeks after taking the dose than those who took the lower 1 mg dose. However, the inoculated patient groups reported side effects such as headache, nausea, and thoughts of suicide.
The trial gives hope to an estimated 100 million people suffering from "treatment resistant" depression with other antidepressants already in use. “ This disease can lead to a number of other problems that have a serious impact on patients and the people around them. Treatment options are often limited and come with annoying or stigmatizing side effects. Therefore, new treatment paradigms are needed and the clinical search for new treatments is important , ”said Dr James Rucker, co-head of King's IoPPN psychoactive trial group and consultant psychiatrist at the South London and Maudsley NHS Foundation Trust. in a statement published by the institution.
" Psilocybin therapy may be a new treatment paradigm, but it needs to be tested in clinical trials ."
Three weeks after taking the drug, along with a couple of therapy sessions, one third of the group went into rapid remission, which is 29% of the group given the 25 mg dose of psilocybin. One in three was no longer depressed at the end of the study, and one in five felt a significant improvement at 12 weeks.
Thanks to our Telegram channel you can stay updated on the publication of new articles of Economic Scenarios.
The article Depression: a hope comes from a substance contained in hallucinogenic mushrooms comes from Economic Scenarios .
This is a machine translation of a post published on Scenari Economici at the URL https://scenarieconomici.it/depressione-una-speranza-viene-da-una-sostanza-contenuta-nei-funghi-allucinogeni/ on Fri, 04 Nov 2022 18:52:16 +0000.